Litigation involving US Patent 11344552

11344552

CSPC Pharmaceutical Group Limited et al. v. Ipsen Biopharm Ltd.

Pending - Instituted

Docket:: IPR2025-00505
Court:: Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office
Filed:: 2025-01-16

π CSPC Pharmaceutical Group Limited π CSPC Ouyi Pharmaceutical Co., Ltd.π Conjupro Biotherapeutics, Inc.Δ Ipsen Biopharm Ltd.

The PTAB instituted this inter partes review on August 14, 2025, after the Acting Director of the USPTO declined Ipsen Biopharm Ltd.'s request for discretionary denial, finding petitioners' arguments persuasive regarding potential material error during the original patent prosecution.

Unified Patents v. Ipsen Biopharm Ltd.

Pending - Instituted

Docket:: IPR2025-01531
Court:: Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office

Patents:11344552

π Unified Patents Δ Ipsen Biopharm Ltd.

This inter partes review was filed by Unified Patents against Ipsen Biopharm Ltd. and subsequently instituted by the PTAB.

IPSEN BIOPHARMACEUTICALS, INC. et al. v. CONJUPRO BIOTHERAPEUTICS, INC. et al.

Administratively terminated

Docket:: 1:2024cv04991
Court:: U.S. District Court for the District of New Jersey
Filed:: 2024-04-15
Terminated:: 2025-09-05

Patents:11344552

π IPSEN BIOPHARMACEUTICALS, INC.π IPSEN BIOPHARM LTD.Δ CONJUPRO BIOTHERAPEUTICS, INC.Δ CSPC PHARMACEUTICAL GROUP LIMITED Δ CSPC OUYI PHARMACEUTICAL CO., LTD.

Filed on April 15, 2024, this ANDA-related patent infringement civil action was later consolidated with case 1:2025cv13647. The consolidated action was directed to be administratively terminated on September 5, 2025.